Riddhi Siddhi Gluco Biols Q3 Profit Halved, Liabilities Surge

COMMODITIES
Whalesbook Logo
AuthorAarav Shah|Published at:
Riddhi Siddhi Gluco Biols Q3 Profit Halved, Liabilities Surge
Overview

Riddhi Siddhi Gluco Biols reported a grim Q3 FY26, with standalone PAT down 66.8% to ₹886.05 lakhs and consolidated PAT from continuing operations down 98.0% to ₹39.30 lakhs. Despite a 169.7% nine-month standalone revenue jump, profits sagged, and standalone liabilities more than doubled to ₹22,384.75 lakhs. Discontinued operations continued to incur losses, with no management guidance provided.

📉 The Financial Deep Dive

The Numbers:

Riddhi Siddhi Gluco Biols Limited has posted a deeply concerning performance in its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26).

On a standalone basis:

  • Revenue from operations for Q3 FY26 saw a slight year-on-year (YoY) decrease of 2.1% to ₹3,123.92 lakhs.
  • Profit Before Tax (PBT) witnessed a severe drop of 51.0% YoY to ₹1,096.22 lakhs.
  • Profit After Tax (PAT) plummeted by 66.8% YoY to ₹886.05 lakhs.
  • Earnings Per Share (EPS) fell sharply from ₹37.35 in Q3 FY25 to ₹12.43 in Q3 FY26.

For the nine months ended December 31, 2025 (9M FY26), standalone revenue surged by an impressive 169.7% YoY to ₹20,194.52 lakhs. However, this top-line growth did not translate to profitability, with PBT declining 22.4% and PAT falling 34.7%. The nine-month EPS stood at ₹71.71, down from ₹118.01 in the corresponding prior period.

On a consolidated basis (continuing operations):

  • Q3 FY26 revenue decreased by 9.6% YoY to ₹4,008.20 lakhs.
  • PBT plummeted by 83.2% YoY to ₹249.47 lakhs.
  • PAT after tax crashed by 98.0% YoY to a mere ₹39.30 lakhs.
  • The consolidated EPS from continuing operations was ₹0.55, a stark contrast to ₹26.71 in the prior year.

For 9M FY26 consolidated (continuing operations), revenue more than doubled, rising 110.5% YoY to ₹22,679.28 lakhs. Despite this significant revenue growth, PBT declined by 36.2% and PAT fell by 58.1%, resulting in a 9-month consolidated EPS of ₹35.53, down from ₹84.72.

The Quality & Margins:
The company's profitability metrics have deteriorated significantly. While specific EBITDA figures are not provided, the steep decline in PBT and PAT relative to revenue clearly indicates substantial margin compression across both standalone and consolidated segments. The standalone PBT margin for Q3 FY26 was approximately 20.47% (calculated on total income), a sharp fall from prior periods. Consolidated continuing operations PBT margin in Q3 FY26 was roughly 6.22%, suggesting severe operational or cost pressures.

Discontinued Operations:
Losses from discontinued operations, primarily the paper division of a subsidiary, persisted. The company reported an after-tax loss of ₹167.92 lakhs for Q3 FY26 and ₹482.32 lakhs for the nine months. A substantial impairment loss of ₹6,956.48 lakhs was recognised in the prior nine-month period ended December 31, 2024, related to asset disposal from these operations.

Balance Sheet:
Standalone total assets grew to ₹1,99,770.73 lakhs as of December 31, 2025, from ₹1,83,273.48 lakhs at the end of FY25. However, standalone total liabilities saw a more than doubling, increasing from ₹11,541.61 lakhs to ₹22,384.75 lakhs during the same period, signalling heightened financial leverage and risk.

🚩 Risks & Outlook

Specific Risks:

  • Profitability Erosion: The drastic YoY decline in profitability, particularly on a consolidated basis for continuing operations, is a major concern. The inability to convert significant revenue growth (in nine-month periods) into profits highlights deep-seated operational or cost issues.
  • Discontinued Operations: Persistent losses from the paper division continue to drag down overall performance, requiring continuous management attention.
  • Rising Liabilities: The substantial increase in standalone liabilities indicates growing financial obligations and potential strain on liquidity. This warrants closer scrutiny of the company's debt structure and servicing capabilities.
  • Contingent Liabilities: The company faces ongoing tax appeals with the Income Tax Appellate Tribunal and SEBI matters (penalty, Minimum Public Shareholding directives) which are being challenged before the Securities Appellate Tribunal (SAT). These unresolved issues pose potential future financial risks.
  • Lack of Guidance: The absence of any management guidance or outlook in this filing leaves investors with considerable uncertainty about future performance, strategic direction, and recovery prospects.

The Forward View:
Investors must closely monitor the company's ability to stem the tide of profitability decline, especially in its continuing operations. Key watchpoints include:

  • Efforts to improve operational efficiencies and control costs to restore margins.
  • The outcome of the tax and SEBI-related legal challenges.
  • The performance and potential divestment progress of discontinued operations.
  • Management commentary in future communications regarding strategy and financial recovery.

No analyst EPS estimates were available in the provided filing for comparison against the reported EPS figures.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.